Issue Date: January 14, 2013
Bind And Amgen To Inhibit Kinases
Bind Biosciences will work with Amgen to develop kinase inhibitor nanomedicines to treat a range of solid tumors. Cambridge, Mass.-based Bind says it could receive up-front and development milestone payments totaling $46.5 million and up to $134 million more for regulatory and sales milestones. Bind is developing targeted and programmable therapeutics it calls Accurins. The partners are looking to develop a new Accurin around a proprietary kinase inhibitor from Amgen.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society